Table 1.

Demographics of patients treated with DAA

Age, median (IQR)	53 (43–58)
Sex—male (%)	66
Genotype (%)
1a	43
1b	10
2	5
3	40
Other	2
Fibrosis stage (%)
F0	18
F1	30
F2	16
F3	10
F4	26
Treatment history (%)
Naïve	78
TE no PI	18
TE and PI	3
Prior DAA failure	1
Duration of treatment, weeks (%)
8	15
12	70
24	15

DAA, direct-acting antiviral agent; PI, protease inhibitor; TE, treatment experienced.